On June 23, Liquidia Technologies rose 5.18% in regular trading, trading at $74.64/share, with Turnover of $73.327 million. The stock surpassed its prior 52-week high of $73.22, reaching a new all-time high.

Within the Pharmacy sector where Liquidia Technologies belongs, individual stock performance was mixed. Among individual stocks, Definium Therapeutics up 50.82%, Novo-Nordisk up 7.35%, Eli Lilly up 1.38%, Johnson & Johnson up 1.16%, Pfizer down 0.42%.

Liquidia Corporation is a biopharmaceutical company focused on pulmonary arterial hypertension (PAH) treatment. Its lead product candidate YUTREPIA is an inhaled dry powder formulation of treprostinil for PAH and pulmonary hypertension associated with interstitial lung disease. The company also offers Remodulin and holds a license agreement for L606, an inhaled sustained-release formulation of Treprostinil.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)